Menu

  • Products & Technologies
  • Clinical Evidence
  • Media Kit
  • Reimbursement
  • Medtronic Academy

    • Evidence for long-term, significant relief

    Results of the 2023 NOVA randomized clinical trial (RCT)1 demonstrate that Differential Target Multiplexed™ spinal cord stimulation (DTM™ SCS) therapy provides significant, long-term pain relief for patients who have:

    • Degenerative disc disease (DDD)
    • Herniated disc (HD)
    • Radicular pain syndrome (RPS)

    The NOVA RCT was an on-label, prospective, multicenter, randomized controlled trial that compared Medtronic DTM™ SCS to conventional SCS out to 12 months for patients who were not eligible for spine surgery, but had a diagnosis of DDD, HD, or RPS.

    View NOVA 1-pager (open in new window)

    DTM™ SCS therapy outcomes

    Leg pain relief†


    DTM™ SCS provided sustained leg pain relief with a mean VAS score of 1.28 cm at 12 months

    Back pain relief†


    DTM™ SCS provided sustained back pain relief with a mean
    VAS score of 1.46 cm at 12 months

    Download the NOVA study

    Superior back pain relief compared to
    conventional stimulation

    Key takeaways for pain relief outcomes

    • DTM™ SCS was proven effective at treating chronic back pain patients with DDD, HD, or RPS who are ineligible for spine surgery.
    • Outcomes at the 12-month follow-up (n=51 subjects for back pain; n=37 subjects for leg pain) included:
      • 90.5% back pain responder rate with DTM™ SCS
      • 90.6% of leg pain responder rate with DTM™ SCS
      • Sustained back pain relief with a mean VAS reduction of 6.4 cm (0.3 standard error) from baseline
      • Sustained leg pain relief with a mean VAS reduction of 6.2 cm (0.4 standard error) from baseline
    • DTM™ SCS provided a 65.5% higher back pain responder rate and 55.8% higher leg pain responder rate than conventional SCS at 12 months (p < 0.0001).
    • The primary endpoint was met with DTM™ SCS providing a 57.1% higher back pain responder rate than conventional SCS at 3 months (p <0.0001).
    • DTM™ SCS back pain responder rate was 3.6 times higher than conventional SCS at 12 months (p < 0.0001).

    Safety outcomes

    The incidence of device-related adverse events and serious adverse events were consistent with other SCS studies.

    Back pain responder rate†


    90.5% — DTM™ SCS back pain responder rate‡ reported at 12 months
    (≥50% improvement)

    Leg pain responder rate†


    90.6% — DTM™ SCS leg pain responder rate reported at 12 months
    (≥50% improvement)

    View publications

    Back pain profound responder rate
    (≥80% back pain relief)†



    76% — 7 out of 10 patients were profound back pain responders
    (≥80% relief) with DTM™ at 12 months.

    Leg pain profound responder rate
    (≥80% leg pain relief)†



    78% — 7 out of 10 patients were profound leg pain responders
    (≥80% relief) with DTM™ at 12 months.

    Quality-of-life outcomes indicated for chronic back pain patients with DDD, HD, or RPS

    • DTM™ SCS provided sustained improvements in the degree of disability and quality of life at a 12-month follow-up.
    • >87% of subjects reported minimal to moderate disability with DTM™ SCS at 12 months versus 26.6% at baseline with the Oswestry Disability Index.
    • >92% of subjects were satisfied or very satisfied with DTM™ SCS at 12 months.
    • >95% of subjects reported being in a better health state with DTM™ SCS at 12 months.

    Reduced disability

    87.5%

    of patients report moderate to minimal disability at 12 months compared to 52% baseline using the ODI.1

    Health improvement

    89%

    of patients felt much improved with DTM™ therapy during their 12-month visit through the Patient Global Impression of Change.1

    Therapy satisfaction

    93%

    of patients felt very satisfied or satisfied with their DTM™ SCS programming at 12 months.1